CytoDyn, Inc., a development stage biotechnology research company, engages in the discovery and development of a treatment for human immunodeficiency virus. Its treatment bolsters the human immune system by an injection of monoclonal antibodies. The company’s lead drug candidate, Cytolin, a monoclonal antibody that protects CD4 cells from CD8 cells, which prevents the weakening of the immune system. Its other products in pipeline include Formaxycin, a drug for the treatment of cancerous and pre cancerous cells. The company is also collaborating with another biotech company for the development of drugs for treating neuropsychiatric disorders. It has a strategic alliance with Utek Corp. CytoDyn is headquartered in Santa Fe, New Mexico.